If GLP-1 drugs are the breakthrough of this decade, diet may be the most overlooked way to enhance their effect.
These medications have transformed the treatment of obesity and type 2 diabetes, delivering levels of weight loss and glycemic control that were once unimaginable. They are, without question, one of the most important pharmacologic advances in modern medicine.
But amid this progress, we are overlooking a simpler and more fundamental question. Have we done everything we can to activate the body’s own GLP-1 system before we replace it?
GLP-1 is not just a drug target. It is a hormone, part of a complex physiological network that regulates insulin secretion, appetite, and gastric emptying. It is produced naturally in the gut in response to the foods we eat.
Because diet does not merely support metabolic health. It directly influences the very pathway we are now trying to mimic pharmacologically.
When we eat, nutrients interact with intestinal L-cells, triggering GLP-1 release. Fiber is fermented by gut bacteria into short-chain fatty acids that further stimulate this response. Whole foods slow gastric emptying, prolonging satiety signals. These are coordinated pathways that together shape metabolic regulation.
In other words, diet activates the GLP-1 system, not through a single signal, but through many, simultaneously. This is fundamentally different from how GLP-1 drugs work. Pharmacologic agents deliver a strong, targeted signal to the receptor. They are powerful, but they operate on a single axis of a broader system.
Diet, by contrast, modulates that system as a whole. In our randomized clinical trials, plant-based dietary interventions have improved insulin sensitivity, reduced liver and muscle fat, and in some cases led to remission of type 2 diabetes, effects that reflect coordinated changes in metabolic physiology, not a single pathway.
This distinction has real clinical implications. In controlled trials, meals built around whole plant foods have been shown to elicit greater incretin responses than calorie-matched meals rich in animal products. More broadly, dietary patterns rich in whole grains, legumes, fruits, and vegetables are consistently associated with improved glycemic control, reduced body weight, and lower cardiovascular risk.
Yet in clinical practice, nutrition is often treated as secondary, something to address after pharmacotherapy is initiated. This is a missed opportunity. The goal is not to choose between diet and medication. For many patients, GLP-1 drugs are essential. But framing the discussion as a choice obscures a more effective strategy: integration.
Diet and pharmacologic therapy operate through overlapping pathways. When used together, they can reinforce one another, enhancing efficacy and, in some cases, allowing for lower medication doses.
Instead of viewing GLP-1 as something we administer, we can begin to see it as something we restore. This shift, from replacement to amplification, reflects a broader principle in medicine. The most effective therapies work by supporting physiology, not overriding it.
GLP-1 drugs have changed what is possible in metabolic care. The next step is to ask how we can make them work even better. And that may begin with a simple question. What are we feeding the system we are trying to treat?
Hana Kahleova is an endocrinologist.
